Floatz logo

L-Bupivacaine

Hypotensive Disorder

University Hospital DubravaSmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

0 Active assets in the Hypotensive Disorder cohort.

Asset / SponsorPhaseRating
M-Sympathol
The Second Affiliated Hospital of Dalian Medical University
Phase 4BB
Ephedrine, Anhydrous
University Hospital, Clermont-Ferrand
Phase 4BB
Noradrenaline
The Second Affiliated Hospital of Dalian Medical University
Phase 3B
Imisopasem Manganese
MetaPhore Pharmaceuticals
Phase 1/2CCC
Marcaine
Ankara University
UnknownD
Midodrine
The Cleveland Clinic
N/AD
Fentanyl
Ankara University
UnknownD
Nitroglycerin Tablets
Liang Bing
N/ANR

Same molecule, other indications

L-Bupivacaine is also rated in:

breast neoplasmActive
BB
Indicative · Phase 4
65 / 100
View asset →
chronic pain syndromeActive
B
Indicative · Phase 4
61 / 100
View asset →
breast cancerActive
B
Indicative · Phase 4
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →